STXS forecasts $8M in recurring revenue for Q4 2026 as MAGiC system adoption faces supply constraints.
Stereotaxis expects recurring revenue to hit $8M in Q4 2026, driven by recent regulatory approvals for its new robot, catheters, and digital surgery system. The company cited supply constraints for its MAGiC system as a limiting factor in adoption growth.
Management highlighted a milestone-rich period in Q2 2026, including approvals for therapeutic and diagnostic catheters. The company aims to commercialize these products to support revenue expansion, though supply chain challenges persist.
No immediate market reaction was disclosed in the earnings call insights.